<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR941230-2-00034</title>
	</head>
	<body>
		<main>
			<p><!-- PJG ITAG l=10 g=1 f=2 --> EFFECTIVE DATE: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  December 30, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> <!-- PJG STAG 4703 -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=41 g=1 f=1 -->  <RINDOCK>[Docket No. 93N&hyph;0184]</RINDOCK> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 -->  <DOCTITLE>Barr Laboratories, Inc.; Withdrawal of Proposal To Refuse To Approve Certain Abbreviated Applications <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG --> </DOCTITLE> <!-- PJG 0012 frnewline -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Food and Drug Administration, HHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Notice. <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> The Food and Drug Administration (FDA) is withdrawing a notice proposing to refuse to approve certain original and supplemental abbreviated new drug applications (ANDA's) and certain original and supplemental abbreviated antibiotic applications (AADA's) submitted by Barr Laboratories, Inc., 2 Quaker Rd., Pomona, NY 10970 (Barr). That notice also provided Barr with an opportunity for a hearing. The basis for this withdrawal is Barr's present compliance with current good manufacturing practice (CGMP), so that the methods Barr uses in, and the facilities and controls it uses for, the manufacturing, processing, and packing of its drug products are adequate to assure and preserve its products' identity, strength, quality, and purity.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUMMARY> <DATE> <!-- PJG ITAG l=10 g=1 f=2 --> EFFECTIVE DATE: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  December 30, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </DATE> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Harry T. Schiller, Center for Drug Evaluation and Research (HFD&hyph;366), Food and Drug Administration, 7500 Standish Place, Rockville, MD 20855, 301&hyph;594&hyph;2041. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FURTHER> <SUPPLEM> <!-- PJG ITAG l=10 g=1 f=2 --> SUPPLEMENTARY INFORMATION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> In a notice published in the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  of May 28, 1993 (58 FR 31035)), FDA proposed to refuse to approve certain original and supplemental ANDA's and AADA's submitted by Barr. The basis for the proposal was that the drug products that were the subjects of these original applications and supplements were not being manufactured in compliance with the CGMP regulations. A detailed description of the deficiencies and the basis for the agency's proposal can be found in the May 28, 1993,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  notice. In a notice of opportunity for hearing (NOOH), the agency proposed to refuse approval of the following original ANDA's and AADA's: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> AADA 63&hyph;291, Minocycline Hydrochloride Capsules, 100 milligrams (mg); <!-- PJG 0012 frnewline --> AADA 63&hyph;309, Minocycline Hydrochloride Tablets, 100 mg; <!-- PJG 0012 frnewline --> AADA 63&hyph;319, Minocycline Hydrochloride Tablets, 50 mg; <!-- PJG 0012 frnewline --> ANDA 72&hyph;916, Sulindac Tablets, 200 mg; <!-- PJG 0012 frnewline --> ANDA 72&hyph;964, Sulindac Tablets, 150 mg; <!-- PJG 0012 frnewline --> ANDA 74&hyph;049, Atenolol Tablets, 50 mg and 100 mg.  <!-- PJG 0012 frnewline --> In the notice, FDA also proposed to refuse to approve the following supplemental ANDA's and AADA's: <!-- PJG 0012 frnewline --> AADA 62&hyph;418/S&hyph;014, Doxycycline Hyclate Capsules, 50 and 100 mg; <!-- PJG 0012 frnewline --> AADA 62&hyph;773/S&hyph;005, Cephalexin Capsules, 250 mg; <!-- PJG 0012 frnewline --> AADA 62&hyph;827/S&hyph;006, Cephalexin Tablets, 500 mg; <!-- PJG 0012 frnewline --> ANDA 70&hyph;060/S&hyph;012, S&hyph;017, Methyldopa Tablets, 250 mg; <!-- PJG 0012 frnewline --> ANDA 70&hyph;080/S&hyph;028, S&hyph;029, Ibuprofen Tablets, 600 mg; <!-- PJG 0012 frnewline --> ANDA 70&hyph;103/S&hyph;018, S&hyph;019, Propranolol Hydrochloride Tablets, 40 mg; <!-- PJG 0012 frnewline --> ANDA 70&hyph;319/S&hyph;018, S&hyph;019, Propranolol Hydrochloride Tablets, 10 mg; <!-- PJG 0012 frnewline --> ANDA 70&hyph;320/S&hyph;018, Propranolol Hydrochloride Tablets, 20 mg; <!-- PJG 0012 frnewline --> ANDA 70&hyph;472/S&hyph;004, Lorazepam Tablets, 0.5 mg; <!-- PJG 0012 frnewline --> ANDA 70&hyph;474/S&hyph;004, S&hyph;010, Lorazepam Tablets, 2 mg; <!-- PJG 0012 frnewline --> ANDA 70&hyph;765/S&hyph;010, S&hyph;011, S&hyph;012, S&hyph;013, Chlordiazepoxide and Amitriptyline Hydrochloride Tablets, 5 mg/12.5 mg; <!-- PJG 0012 frnewline --> ANDA 71&hyph;212/S&hyph;003, S&hyph;009, Haloperidol Tablets, 5 mg; <!-- PJG 0012 frnewline --> ANDA 71&hyph;251/S&hyph;005, Triamterene and Hydrochlorothiazide Tablets, 75 mg/50 mg; <!-- PJG 0012 frnewline --> ANDA 71&hyph;462/S&hyph;014, S&hyph;015 Ibuprofen Tablets, 200 mg; <!-- PJG 0012 frnewline --> ANDA 80&hyph;701/S&hyph;079, Prednisone Tablets, 5 mg; <!-- PJG 0012 frnewline --> ANDA 84&hyph;106, S&hyph;065, S&hyph;066, Hydralazine Hydrochloride Tablets, 25 mg; <!-- PJG 0012 frnewline --> ANDA 84&hyph;600/S&hyph;039, Dicyclomine Hydrochloride Tablets, 20 mg; <!-- PJG 0012 frnewline --> ANDA 88&hyph;488/S&hyph;013, Hydroxyzine Pamoate Capsules, 100 mg.  <!-- PJG 0012 frnewline -->  Following the publication of the NOOH, the agency inspected Barr's Northvale, NJ, manufacturing facility from May 2, 1994, through June 10, 1994. FDA also inspected Barr's Pomona, NY, manufacturing facility from June 16 through July 18, 1994. Based on these inspections, the firm's responses to the FDA investigators' observations, and the resolution by consent decree of enforcement litigation concerning Barr's compliance with the CGMP regulations ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> United States <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  v.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Barr Laboratories, Inc <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ., Civ. No. 92&hyph;2684 (S.D.N.Y.)), FDA has concluded that Barr is now complying with the CGMP regulations in manufacturing drug products. Accordingly, the May 28, 1993,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  notice proposing to refuse to approve certain applications and supplements is withdrawn. The withdrawal of the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  notice does not constitute approval of the original applications and supplements; the agency is continuing its review of those applications and supplements to ensure that they meet all statutory requirements for approval in addition to compliance with CGMP. This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec. 505 (21 U.S.C. 355)) and under the authority delegated to the Director of the Center of Drug Evaluation and Research (21 CFR 5.82).  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: December 20, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> Janet Woodcock, <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Director, Center for Drug Evaluation and Research. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 95&hyph;32138 Filed 12&hyph;29&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4160&hyph;01&hyph;F <!-- PJG /ITAG --> </BILLING>  <!-- PJG 0012 frnewline -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            